nomlabofusp
nomlabofusp: developed by 1 company · 2 clinical trials tracked.
nomlabofusp evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could nomlabofusp → LRMR affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Larimar Therapeutics, Inc. (LRMR) | Phase 3 |
Clinical Trials (2)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
Primary endpoint: Change from baseline in Upright Stability Score (USS) subscale E of modified Friedreich's Ataxia Rating Scale (mFARS) at Week 72 (Region-specific)
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Nomlabofusp in Adolescents and Children With Friedreich's Ataxia
Primary endpoint: Number of AEs, TEAEs, related TEAEs, Grade 3/4 TEAEs, and SAEs
Frequently asked questions
Who is developing nomlabofusp?
nomlabofusp is being developed by Larimar Therapeutics, Inc..
How many clinical trials involve nomlabofusp?
BioSniper tracks 2 clinical trials involving nomlabofusp.